FDA Brief

Warning letters Drugs

FDA warning letter to

SV Labs Corporation

High riskIssued Dec 9, 2025Posted Dec 23, 2025Center for Veterinary Medicine

SV Labs released microbe-contaminated OTC drug products and lacked water, process and quality controls, FDA says.

What happened

FDA inspected SV Labs Prescott Corporation in Prescott, Wisconsin, from June 10 to 13, 2025, and reviewed the company's July 7, 2025 response to the inspection findings (Form FDA 483, the list of observations given at the end of an inspection). Investigators found that a sunscreen lotion lot with a "too numerous to count" microbial result was released to a customer without investigation, and that Burkholderia cepacia complex bacteria were found in a topical fungicide animal drug lot, traced to production line swabs. FDA also found the company's water system had dead legs and a history of microbial failures, that manufacturing and cleaning processes were not validated, and that the quality unit did not provide adequate oversight.

What FDA found

  1. The company released a sunscreen lotion lot that failed its microbial count test, and did not investigate the cause before shipping it to the customer.

    21 CFR 211.192
  2. After finding Burkholderia cepacia contamination in a fungicide lot, the company did not check other batches made on the same equipment and did not properly evaluate its water system as the source.

    21 CFR 211.192
  3. The water used as an ingredient was not shown to be suitable, and the old water system had two dead legs that let microbes grow in stagnant areas.

    21 CFR 211.63
  4. The company had no process validation studies to show its manufacturing processes work consistently, and had not validated cleaning of shared filling equipment.

    21 CFR 211.100(a)
  5. The quality unit failed to control who could change master records, set adequate lab specifications and test methods, run a proper stability program, and keep complete laboratory records.

    21 CFR 211.22 (with 21 CFR 211.68(b), 211.160(b), 211.166(a), 211.194(a))

What FDA wants

FDA tells the company to reply in writing within 15 working days describing corrections and preventive actions. It also asks for a retrospective review of all drug products still within expiry in the U.S. market, BCC testing of retained samples, water system validation data, process and cleaning validation plans, a quality unit remediation plan, and recommends hiring a qualified CGMP consultant.

Who should pay attention

  • brands that contract out OTC human or animal drug manufacturing
  • companies buying OTC sunscreens or topical drugs made by contract manufacturers
  • firms making aqueous drug products with pharmaceutical water systems

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk